{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:19:26Z","timestamp":1777673966554,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02398-2","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T10:23:29Z","timestamp":1745663009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of bronchial artery infusion immunotherapy: from comparative analysis in beagle canines to clinical validation"],"prefix":"10.1007","volume":"16","author":[{"given":"Bin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"16","key":"2398_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330.","journal-title":"Cancer"},{"issue":"7689","key":"2398_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"key":"2398_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168661","author":"R Nooreldeen","year":"2021","unstructured":"Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22168661.","journal-title":"Int J Mol Sci"},{"key":"2398_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2363","volume":"375","author":"M Miller","year":"2021","unstructured":"Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375: n2363.","journal-title":"BMJ"},{"key":"2398_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107319","volume":"184","author":"Y Luo","year":"2023","unstructured":"Luo Y, Zhang Z, Guo X, Tang X, Li S, Gong G, Gao S, Zhang Y, Lin S. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis. Lung Cancer. 2023;184: 107319.","journal-title":"Lung Cancer"},{"issue":"9","key":"2398_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","volume":"33","author":"F Cortiula","year":"2022","unstructured":"Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol. 2022;33(9):893\u2013908.","journal-title":"Ann Oncol"},{"issue":"7","key":"2398_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2398_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, Rodr\u00edguez-Abreu D. pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"key":"2398_CR9","doi-asserted-by":"publisher","first-page":"4518898","DOI":"10.1155\/2022\/4518898","volume":"2022","author":"X Yang","year":"2022","unstructured":"Yang X, Zeng Y, Tan Q, Huang Z, Jia J, Jiang G. Efficacy of PD-1\/PD-L1 inhibitors versus chemotherapy in lung cancer with brain metastases: a systematic review and meta-analysis. J Immunol Res. 2022;2022:4518898.","journal-title":"J Immunol Res"},{"key":"2398_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215143","author":"E Pasqualotto","year":"2023","unstructured":"Pasqualotto E, Moraes FCA, Chavez MP, Souza MEC, Rodrigues A, Ferreira ROM, Lopes LM, Almeida AM, Fernandes MR, Santos N. PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for resectable non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15215143.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2398_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, Rodr\u00edguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2398_CR12","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492\u2013504.","journal-title":"Ann Oncol"},{"issue":"1","key":"2398_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"10027","key":"2398_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"19","key":"2398_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"2398_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","volume":"171","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, Lin Y, Wang S, Zhang W, Sun L, Yang Y. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56\u201360.","journal-title":"Lung Cancer"},{"issue":"26","key":"2398_CR17","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065\u201376.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2398_CR18","first-page":"463","volume":"20","author":"M Kitano","year":"2024","unstructured":"Kitano M, Honda T, Hikita E, Masuo M, Miyazaki Y, Kobayashi M. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience. Asia Pac J Clin Oncol. 2024;20(4):463\u201371.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"2398_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","volume":"318","author":"SM Blum","year":"2023","unstructured":"Blum SM, Rouhani SJ, Sullivan RJ. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev. 2023;318(1):167\u201378.","journal-title":"Immunol Rev"},{"key":"2398_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110747","volume":"161","author":"G He","year":"2023","unstructured":"He G, Yang K, Zhang X, Pan J, Han A, Gao Z, Li Y, Wang W. Bronchial artery chemoembolization with drug-eluting beads versus bronchial artery infusion followed by polyvinyl alcohol particles embolization for advanced squamous cell lung cancer: a retrospective study. Eur J Radiol. 2023;161: 110747.","journal-title":"Eur J Radiol"},{"issue":"6","key":"2398_CR21","first-page":"2554","volume":"25","author":"XF Liu","year":"2021","unstructured":"Liu XF, Lin H, Wang Q, Mu M, Pan P, Tian FF, Zhang R, Zhao WG, Bao PT. Drug-eluting bead bronchial arterial chemoembolization vs chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life. Eur Rev Med Pharmacol Sci. 2021;25(6):2554\u201366.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"2398_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00280-018-3757-7","volume":"83","author":"AF Alharbi","year":"2019","unstructured":"Alharbi AF, Kratzke RA, D\u2019Cunha J, Maddaus MA, Sanghavi K, Kirstein MN. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. Cancer Chemother Pharmacol. 2019;83(2):387\u201391.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2398_CR23","doi-asserted-by":"crossref","unstructured":"Francis DM, Manspeaker MP, Schudel A, Sestito LF, O'Melia MJ, Kissick HT, Pollack BP, Waller EK, Thomas SN. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020, 12(563).","DOI":"10.1126\/scitranslmed.aay3575"},{"key":"2398_CR24","doi-asserted-by":"publisher","first-page":"1447021","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024;15:1447021.","journal-title":"Front Immunol"},{"issue":"1","key":"2398_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"suppl_12","key":"2398_CR26","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28(suppl_12):xii33\u201343.","journal-title":"Ann Oncol"},{"issue":"10183","key":"2398_CR27","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"14","key":"2398_CR28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, \u00d6zg\u00fcro\u011flu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"25","key":"2398_CR29","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"8","key":"2398_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/0277-5379(91)90278-L","volume":"27","author":"E Shimizu","year":"1991","unstructured":"Shimizu E, Nakamura Y, Mukai J, Tani K, Yamashita T, Hojo F, Hashimoto Y, Ogura T. Pharmacokinetics of bronchial artery infusion of mitomycin in patients with non-small cell lung cancer. Eur J Cancer. 1991;27(8):1046\u20138.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2398_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1378\/chest.115.5.1230","volume":"115","author":"MA Maddaus","year":"1999","unstructured":"Maddaus MA. Bronchial artery chemotherapy\u2014a future? Chest. 1999;115(5):1230\u20131.","journal-title":"Chest"},{"issue":"9","key":"2398_CR32","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.21037\/qims-23-287","volume":"13","author":"S Xu","year":"2023","unstructured":"Xu S, Li YM, Bie ZX, Li XG. Drug-eluting beads bronchial arterial chemoembolization\/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study. Quant Imaging Med Surg. 2023;13(9):6241\u201356.","journal-title":"Quant Imaging Med Surg"},{"issue":"4","key":"2398_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2398_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271\u201381.","journal-title":"Chest"},{"issue":"9","key":"2398_CR35","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.21873\/anticanres.15929","volume":"42","author":"K Sakuma","year":"2022","unstructured":"Sakuma K, Kii T, Takahashi H, Suzuki S, Yoshikawa K, Ogawa T, Tanaka A. An in vivo study of local administration of low-dose anti-PD-1 antibody using an oral cancer cell line. Anticancer Res. 2022;42(9):4293\u2013303.","journal-title":"Anticancer Res"},{"key":"2398_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.22203\/eCM.v036a04","volume":"36","author":"R Bell","year":"2018","unstructured":"Bell R, Robles-Harris MA, Anderson M, Laudier D, Schaffler MB, Flatow EL, Andarawis-Puri N. Inhibition of apoptosis exacerbates fatigue-damage tendon injuries in an in vivo rat model. Eur Cell Mater. 2018;36:44\u201356.","journal-title":"Eur Cell Mater"},{"issue":"4","key":"2398_CR37","first-page":"771","volume":"92","author":"JYJ Wang","year":"2019","unstructured":"Wang JYJ. Cell death response to DNA damage. Yale J Biol Med. 2019;92(4):771\u20139.","journal-title":"Yale J Biol Med"},{"issue":"7","key":"2398_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2398_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39\u201353.","journal-title":"Cell"},{"issue":"8","key":"2398_CR40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1753465817717169","volume":"11","author":"J Zhu","year":"2017","unstructured":"Zhu J, Zhang HP, Jiang S, Ni J. Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer. Ther Adv Respir Dis. 2017;11(8):301\u20139.","journal-title":"Ther Adv Respir Dis"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02398-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T10:23:30Z","timestamp":1745663010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02398-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02398-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments adhered to NIH guidelines and were approved by the IACUC of The First Affiliated Hospital of Chongqing Medical University. The human-subject study followed the Declaration of Helsinki, was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University, and obtained informed consent from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"621"}}